Better to be in The Placebo Arm for Trials of Neurological Therapies?
Patients with progressive neurodegenerative diseases often pursue trial entry seeking to access cutting edge therapies. However, cutting edge therapies for neurodegenerative diseases tend to have higher adverse event rates and underperform placebo. This essay argues that patients seeking trial entry...
Main Author: | Jonathan Kimmelman |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2018-04-01
|
Series: | Cell Transplantation |
Online Access: | https://doi.org/10.1177/0963689718755708 |
Similar Items
-
Efficacy of antidepressants over placebo is similar in two-armed versus three-armed or more-armed randomized placebo-controlled trials.
by: Ogawa, Y, et al.
Published: (2017) -
Differences between experimental and placebo arms in manual therapy trials: a methodological review
by: Giandomenico D’Alessandro, et al.
Published: (2022-08-01) -
Correction: Differences between experimental and placebo arms in manual therapy trials: a methodological review
by: Giandomenico D’Alessandro, et al.
Published: (2023-02-01) -
Minimizing ICU Neurological Dysfunction with Dexmedetomidine-induced Sleep (MINDDS): Protocol for a randomised, double-blind, parallel-arm, placebo-controlled trial
by: Shelton, Kenneth T, et al.
Published: (2020) -
Let’s do better: public representations of COVID-19 science
by: Timothy Caulfield, et al.
Published: (2021-03-01)